Intuitive Surgical beat Q4 earnings forecasts while securing regulatory approvals in Europe and Japan for its da Vinci 5 surgical system. The dual clearances open access to markets representing $2.3 billion in annual surgical robotics spending.
The da Vinci 5 system introduces force feedback and enhanced imaging capabilities unavailable in previous generations. European CE Mark approval covers all 27 EU member states plus Norway, Iceland, and Liechtenstein. Japan's PMDA clearance follows a 14-month review process that included clinical data from 847 procedures across 12 surgical specialties.
Intuitive reported strong Q4 placement activity, with 415 da Vinci systems installed globally during the quarter. This marks a 22% increase over Q4 2025. The company's installed base now exceeds 9,200 systems across 71 countries.
Healthcare systems are allocating larger capital budgets to surgical robotics as procedure volumes recover post-pandemic. U.S. hospitals increased robotics spending by 31% in 2025, according to ECRI Institute data. European and Asian markets are following similar trajectories as reimbursement policies expand to cover robotic-assisted procedures.
The da Vinci 5 regulatory approvals arrive as competitors accelerate development timelines. Medtronic's Hugo system has captured 8% market share since its 2023 launch, while CMR Surgical's Versius platform operates in 85 hospitals across Europe and Asia. Johnson & Johnson discontinued its Ottava program in January 2026, citing technical challenges in autonomous navigation systems.
Intuitive's procedure volumes grew 17% year-over-year in Q4, driven by expansion in thoracic surgery and gynecology applications. The company projects international revenue will grow 28-32% annually through 2027 as newly approved markets scale adoption. Each da Vinci 5 system generates $80,000-$120,000 in recurring instrument and service revenue per year.
Autonomous features in the da Vinci 5 include AI-powered tissue classification and automated suturing assistance. These capabilities require surgeon oversight but reduce procedure times by 12-18% in clinical trials. Regulatory agencies in both Europe and Japan mandated post-market surveillance protocols to monitor autonomous system performance across real-world clinical settings.